Treatment of Alzheimer’s disease (AD) patients with the antidepressant fluoxetine is known to improve memory and cognitive function. However, the mechanisms underlying these effects are largely unknown. To unravel these mechanisms, we aimed to treat APPswe/PS1dE9 mice with fluoxetine. Unexpectedly, with time, an increased number of animals displayed seizure behavior and died. Although spontaneous behavioral seizures have been reported previously in this mouse model, the observation of seizures and death consequential to fluoxetine treatment is new. Our results warrant further research on the underlying mechanisms as this may refine the treatment of AD patients.
ParnettiL, AmiciS, LanariA, GallaiV (2001) Pharmacological treatment of non-cognitive disturbances in dementia disorders. Mech Ageing Dev122, 2063–2069.
2.
HenryG, WilliamsonD, TampiRR (2011) Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen26, 169–183.
3.
KessingLV, FormanJL, AndersenPK (2011) Do continued antidepressants protect against dementia in patients with severe depressive disorder?Int Clin Psychopharmacol26, 316–322.
4.
MosselloE, BoncinelliM, CaleriV, CavalliniMC, PalermoE, Di BariM, TilliS, SarconeE, SimoniD, BiaginiCA, MasottiG, MarchionniN (2008) Is antidepressant treatment associated with reduced cognitive decline in Alzheimer’s disease?Dement Geriatr Cogn Disord25, 372–379.
5.
MowlaA, MosavinasabM, HaghshenasH, Borhani HaghighiA (2007) Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer’s dementia? A double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol27, 484–487.
6.
MowlaA, MosavinasabM, PaniA (2007) Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol27, 67–70.
7.
DongH, GoicoB, MartinM, CsernanskyCA, BertchumeA, CsernanskyJG (2004) Modulation of hippocampal cell proliferation, memory, and amyloid plaque deposition in APPsw (Tg2576) mutant mice by isolation stress. Neuroscience127, 601–609.
8.
NelsonRL, GuoZ, HalagappaVM, PearsonM, GrayAJ, MatsuokaY, BrownM, MartinB, IyunT, MaudsleyS, ClarkRF, MattsonMP (2007) Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol205, 166–176.
9.
CirritoJR, DisabatoBM, RestivoJL, VergesDK, GoebelWD, SathyanA, HayrehD, D’AngeloG, BenzingerT, YoonH, KimJ, MorrisJC, MintunMA, ShelineYI (2011) Serotonin signaling is associated with lower amyloid-beta levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A108, 14968–14973.
10.
IvkovicM, DamjanovicA, Jasovic-GasicM, PaunovicVR (2004) The effects of fluoxetine on cognitive functions in animal model of Alzheimer’s disease. Psychiatr Danub16, 15–20.
11.
KeowkaseR, AboukhatwaM, LuoY (2010) Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology59, 358–365.
12.
ShelineYI, WestT, YarasheskiK, SwarmR, JasielecMS, FisherJR, FickerWD, YanP, XiongC, FrederiksenC, GrzelakMV, ChottR, BatemanRJ, MorrisJC, MintunMA, LeeJM, CirritoJR (2014) An antidepressant decreases CSF Abeta production in healthy individuals and in transgenic AD mice. Sci Transl Med6, 236re234
13.
WangJ, ZhangY, XuH, ZhuS, WangH, HeJ, ZhangH, GuoH, KongJ, HuangQ, LiXM (2014) Fluoxetine improves behavioral performance by suppressing the production of soluble beta-amyloid in APP/PS1 mice. Curr Alzheimer Res11, 672–680.
14.
YangC, GuoX, WangGH, WangHL, LiuZC, LiuH, ZhuZX, LiY (2014) Changes in tau phosphorylation levels in the hippocampus and frontal cortex following chronic stress. Braz J Med Biol Res47, 237–244.
15.
SierksmaAS, van den HoveDL, PfauF, PhilippensM, BrunoO, FedeleE, RicciarelliR, SteinbuschHW, VanmierloT, PrickaertsJ (2014) Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D. Neuropharmacology77, 120–130.
16.
BendeleRA, AdamsER, HoffmanWP, GriesCL, MortonDM (1992) Carcinogenicity studies of fluoxetine hydrochloride in rats and mice. Cancer Res52, 6931–6935.
17.
ErenmemisogluA, OzdoganUK, SaraymenR, TutusA (1999) Effect of some antidepressants on glycaemia and insulin levels of normoglycaemic and alloxan-induced hyperglycaemic mice. J Pharm Pharmacol51, 741–743.
18.
GomesKS, de Carvalho-NettoEF, MonteKC, AccoB, NogueiraPJ, Nunes-de-SouzaRL (2009) Contrasting effects of acute and chronic treatment with imipramine and fluoxetine on inhibitory avoidance and escape responses in mice exposed to the elevated T-maze. Brain Res Bull78, 323–327.
19.
MarlattMW, PotterMC, BayerTA, van PraagH, LucassenPJ (2013) Prolonged running, not fluoxetine treatment, increases neurogenesis, but does not alter neuropathology, in the 3xTg mouse model of Alzheimer’s disease. Curr Top Behav Neurosci15, 313–340.
20.
RacineRJ (1972) Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol32, 281–294.
21.
LuttjohannA, FabenePF, van LuijtelaarG (2009) A revised Racine’s scale for PTZ-induced seizures in rats. Physiol Behav98, 579–586.
22.
VosselKA, BeagleAJ, RabinoviciGD, ShuH, LeeSE, NaasanG, HegdeM, CornesSB, HenryML, NelsonAB, SeeleyWW, GeschwindMD, Gorno-TempiniML, ShihT, KirschHE, GarciaPA, MillerBL, MuckeL (2013) Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol70, 1158–1166.
23.
BornHA (2015) Seizures in Alzheimer’s disease. Neuroscience286, 251–263.
24.
ZiyatdinovaS, GureviciusK, KutchiashviliN, BolkvadzeT, NissinenJ, TanilaH, PitkanenA (2011) Spontaneous epileptiform discharges in a mouse model of Alzheimer’s disease are suppressed by antiepileptic drugs that block sodium channels. Epilepsy Res94, 75–85.
MontgomerySA (2005) Antidepressants and seizures: Emphasis on newer agents and clinical implications. Int J Clin Pract59, 1435–1440.
27.
FerreroAJ, CeresetoM, ReinesA, BonavitaCD, SifoniosLL, RubioMC, WikinskiSI (2005) Chronic treatment with fluoxetine decreases seizure threshold in naive but not in rats exposed to the learned helplessness paradigm: Correlation with the hippocampal glutamate release. Prog Neuropsychopharmacol Biol Psychiatry29, 678–686.
28.
PreskornSH, FastGA (1992) Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry53, 160–162.
PuzereyPA, DeckerMJ, GalanRF (2014) Elevated serotonergic signaling amplifies synaptic noise and facilitates the emergence of epileptiform network oscillations. J Neurophysiol112, 2357–2373.
37.
LangeSC, JulienRM, FowlerGW (1976) Biphasic effects of imipramine in experimental models of epilepsy. Epilepsia17, 183–195.
38.
BianchiMT, BotzolakisEJ (2010) Targeting ligand-gated ion channels in neurology and psychiatry: Is pharmacological promiscuity an obstacle or an opportunity?BMC Pharmacol10, 3.
39.
VelascoA, AlamoC, HervasJ, CarvajalA (1997) Effects of fluoxetine hydrochloride and fluvoxamine maleate on different preparations of isolated guinea pig and rat organ tissues. Gen Pharmacol28, 509–512.
40.
MaguireJ, SalpekarJA (2013) Stress, seizures, and hypothalamic-pituitary-adrenal axis targets for the treatment of epilepsy. Epilepsy Behav26, 352–362.
41.
BoloNR, HodeY, NedelecJF, LaineE, WagnerG, MacherJP (2000) Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology23, 428–438.
ChanJ, JonesNC, BushAI, O’BrienTJ, KwanP (2015) A mouse model of Alzheimer’s disease displays increased susceptibility to kindling and seizure-associated death. Epilepsia56, e73–e77.
